DBV Technologies raises $50m via ATM programme with RA Capital
DBV Technologies has completed a $50 million at-the-market (ATM) equity sale to RA Capital Management, issuing 18.3 million new ordinary shares in the form of 3.66 million American Depositary Shares at $13.67 per ADS. The transaction, executed through Citizens JMP Securities as sales agent, is expected to settle on 3 August 2026.
The placement represents a 5.82% dilution to existing shareholders and adds RA Capital as a new named shareholder with a 5.82% stake in the enlarged share capital. Prior to the issuance, the register was led by Baker Brothers Investments (7.93%), Montanova Capital (7.91%), and JP Morgan (7.33%). The price per ADS reflected a negligible 0.15% discount to the closing price of the underlying ordinary shares on Euronext Paris on the day of pricing, with the modest gap attributed to trading timing differences between Nasdaq and Euronext and foreign exchange effects between the dollar and euro.
The new shares were issued under the authorisation granted at DBV's Annual General Meeting on 3 June 2026 and fall within the French regulatory exemption for qualified-investor placements, meaning no AMF prospectus was required. The registration statement filed with the US Securities and Exchange Commission on 27 July 2026 became automatically effective upon filing.
Use of proceeds and pipeline context
DBV did not specify in the release how the $50 million will be deployed, though the company's current focus is its VIASKIN Peanut Patch programme, which is in ongoing clinical trials in toddlers aged one to three and children aged four to seven with peanut allergy. The patch works via epicutaneous immunotherapy (EPIT), delivering microgram quantities of peanut allergen through intact skin to gradually desensitise the immune system, a mechanism DBV describes as distinct from oral immunotherapy approaches.
The company's late-stage positioning and dual Euronext/Nasdaq listing make the ATM structure a practical capital-raising tool: it allows incremental equity issuance at market prices without the cost and timeline of a conventional underwritten offering, and the direct placement to a single institutional investor such as RA Capital simplifies execution further.
Market context
Food allergy therapeutics, particularly peanut allergy, have attracted sustained investor interest following the 2020 approval of Aimmune Therapeutics' Palforzia oral immunotherapy by the FDA, an asset subsequently acquired by Nestlé Health Science. DBV's patch-based approach occupies a differentiated niche, targeting younger age groups and a non-oral delivery route that may offer a more favourable tolerability profile, though head-to-head data versus oral immunotherapy have not been published.
RA Capital, a multi-stage healthcare investment manager, has a track record of leading or participating in late-stage biotech financings where a clear regulatory catalyst is visible. Its entry as a named shareholder at this stage suggests it sees a near-term inflection point in the VIASKIN programme, most likely a clinical readout or regulatory interaction with the FDA. Investors will be watching for any announcement of a primary completion date for the toddler or children trials, and for any pre-NDA meeting outcomes, as these will be the key near-term milestones that determine whether this capital injection represents a bridge to approval or a runway extension for further development work.